Understand the source comparison
Mazdutide vs Tirzepatide: Dual Agonism with Different Targets
Tirzepatide (Mounjaro, Zepbound) is also a dual agonist, but it targets GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors instead of glucagon. GIP enhances insulin secretion and promotes fat storage in adipose tissue under fed conditions.
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Tirzepatide (Mounjaro, Zepbound) is also a dual agonist, but it targets GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors instead of glucagon. GIP enhances insulin secretion and promotes fat storage in adipose tissue under fed conditions. The opposite of what you'd expect in a weight loss compound. The paradox: when GIP receptors are chronically activated at pharmacological doses, adipocytes become insulin-resistant, which reduces lipid uptake and forces the body to oxidize fat for energy instead. This counterintuitive mechanism works, but it's slower to produce metabolic shifts than glucagon's direct hepatic action.
- In the SURMOUNT-1 trial, tirzepatide 15mg weekly produced 20.9% mean weight reduction at 72 weeks in obese adults without diabetes. Mazdutide 6mg achieved 20.2% reduction at 48 weeks in a similar population. Suggesting mazdutide reaches comparable magnitude faster. Tirzepatide's GIP component improves beta-cell function and glycemic control more robustly than mazdutide in type 2 diabetics (A1C reductions of 2.58% vs 1.8%), but mazdutide's glucagon pathway delivers superior hepatic fat clearance and thermogenesis. The trade-off depends on whether the research goal prioritizes glycemic outcomes or metabolic rate enhancement.
- Both compounds outperform single-receptor GLP-1 agonists, but through divergent pathways. Tirzepatide works by making adipose tissue reject incoming lipids; mazdutide works by making the liver oxidize stored lipids. From a synthesis standpoint, mazdutide's peptide sequence is shorter (39 amino acids vs tirzepatide's 39-residue structure with fatty acid modifications), making it slightly more stable during reconstitution and storage at 2–8°C. We've found that peptides with fewer post-translational modifications maintain potency longer once reconstituted with bacteriostatic water.